Cargando…

Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial

INTRODUCTION: Pain is a common and complex symptom of cancer having physical, social, spiritual and psychological aspects. Approximately 70%–80% of cancer patients experiences pain, as reported in India. Ayurveda recommends use of Shodhita (Processed) Bhanga (Cannabis) for the management of pain but...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavhare, Swagata Dilip, Acharya, Rabinarayan, Reddy, R. Govind, Dhiman, Kartar Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891996/
https://www.ncbi.nlm.nih.gov/pubmed/31831967
http://dx.doi.org/10.4103/ayu.AYU_43_19
_version_ 1783475941799886848
author Tavhare, Swagata Dilip
Acharya, Rabinarayan
Reddy, R. Govind
Dhiman, Kartar Singh
author_facet Tavhare, Swagata Dilip
Acharya, Rabinarayan
Reddy, R. Govind
Dhiman, Kartar Singh
author_sort Tavhare, Swagata Dilip
collection PubMed
description INTRODUCTION: Pain is a common and complex symptom of cancer having physical, social, spiritual and psychological aspects. Approximately 70%–80% of cancer patients experiences pain, as reported in India. Ayurveda recommends use of Shodhita (Processed) Bhanga (Cannabis) for the management of pain but no research yet carried out on its clinical effectiveness. OBJECTIVE: To assess the analgesic potential of Jala-Prakshalana (Water-wash) processed Cannabis sativa L. leaves powder in cancer patients with deprived quality of life (QOL) through openlabel single arm clinical trial. MATERIALS AND METHODS: Waterwash processed Cannabis leaves powder filled in capsule, was administered in 24 cancer patients with deprived QOL presenting complaints of pain, anxiety or depression; for a period of 4 weeks; in a dose of 250 mg thrice a day; along with 50 ml of cow’s milk and 4 g of crystal sugar. Primary outcome i.e. pain was measured by Wong-Bakers FACES Pain Scale (FACES), Objective Pain Assessment (OPA) scale and Neuropathic Pain Scale (NPS). Secondary outcome namely anxiety was quantified by Hospital Anxiety and Depression Scale (HADS), QOL by FACT-G scale, performance score by Eastern Cooperative Oncology Group (ECOG) and Karnofsky score. RESULTS: Significant reduction in pain was found on FACES Pain Scale (P < 0.05), OPA (P < 0.05), NPS (P < 0.001), HADS (P < 0.001), FACT-G scale (P < 0.001), performance status score like ECOG (P < 0.05) and Karnofsky score (P < 0.01). CONCLUSION: Jalaprakshalana Shodhita Bhanga powder in a dose of 250 mg thrice per day; relieves cancerinduced pain, anxiety and depression significantly and does not cause any major adverse effect and withdrawal symptoms during trial period.
format Online
Article
Text
id pubmed-6891996
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-68919962019-12-12 Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial Tavhare, Swagata Dilip Acharya, Rabinarayan Reddy, R. Govind Dhiman, Kartar Singh Ayu Original Article INTRODUCTION: Pain is a common and complex symptom of cancer having physical, social, spiritual and psychological aspects. Approximately 70%–80% of cancer patients experiences pain, as reported in India. Ayurveda recommends use of Shodhita (Processed) Bhanga (Cannabis) for the management of pain but no research yet carried out on its clinical effectiveness. OBJECTIVE: To assess the analgesic potential of Jala-Prakshalana (Water-wash) processed Cannabis sativa L. leaves powder in cancer patients with deprived quality of life (QOL) through openlabel single arm clinical trial. MATERIALS AND METHODS: Waterwash processed Cannabis leaves powder filled in capsule, was administered in 24 cancer patients with deprived QOL presenting complaints of pain, anxiety or depression; for a period of 4 weeks; in a dose of 250 mg thrice a day; along with 50 ml of cow’s milk and 4 g of crystal sugar. Primary outcome i.e. pain was measured by Wong-Bakers FACES Pain Scale (FACES), Objective Pain Assessment (OPA) scale and Neuropathic Pain Scale (NPS). Secondary outcome namely anxiety was quantified by Hospital Anxiety and Depression Scale (HADS), QOL by FACT-G scale, performance score by Eastern Cooperative Oncology Group (ECOG) and Karnofsky score. RESULTS: Significant reduction in pain was found on FACES Pain Scale (P < 0.05), OPA (P < 0.05), NPS (P < 0.001), HADS (P < 0.001), FACT-G scale (P < 0.001), performance status score like ECOG (P < 0.05) and Karnofsky score (P < 0.01). CONCLUSION: Jalaprakshalana Shodhita Bhanga powder in a dose of 250 mg thrice per day; relieves cancerinduced pain, anxiety and depression significantly and does not cause any major adverse effect and withdrawal symptoms during trial period. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6891996/ /pubmed/31831967 http://dx.doi.org/10.4103/ayu.AYU_43_19 Text en Copyright: © 2019 AYU (An International Quarterly Journal of Research in Ayurveda) http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Tavhare, Swagata Dilip
Acharya, Rabinarayan
Reddy, R. Govind
Dhiman, Kartar Singh
Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial
title Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial
title_full Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial
title_fullStr Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial
title_full_unstemmed Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial
title_short Management of chronic pain with Jalaprakshalana (water-wash) Shodhita (processed) Bhanga (Cannabis sativa L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial
title_sort management of chronic pain with jalaprakshalana (water-wash) shodhita (processed) bhanga (cannabis sativa l.) in cancer patients with deprived quality of life: an open-label single arm clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891996/
https://www.ncbi.nlm.nih.gov/pubmed/31831967
http://dx.doi.org/10.4103/ayu.AYU_43_19
work_keys_str_mv AT tavhareswagatadilip managementofchronicpainwithjalaprakshalanawaterwashshodhitaprocessedbhangacannabissativalincancerpatientswithdeprivedqualityoflifeanopenlabelsinglearmclinicaltrial
AT acharyarabinarayan managementofchronicpainwithjalaprakshalanawaterwashshodhitaprocessedbhangacannabissativalincancerpatientswithdeprivedqualityoflifeanopenlabelsinglearmclinicaltrial
AT reddyrgovind managementofchronicpainwithjalaprakshalanawaterwashshodhitaprocessedbhangacannabissativalincancerpatientswithdeprivedqualityoflifeanopenlabelsinglearmclinicaltrial
AT dhimankartarsingh managementofchronicpainwithjalaprakshalanawaterwashshodhitaprocessedbhangacannabissativalincancerpatientswithdeprivedqualityoflifeanopenlabelsinglearmclinicaltrial